BeiGene
Etoposide + Cisplatin/Carboplatin(BeiGene)은 Extensive Stage Lung Small Cell Cancer 표적 치료제로, Extensive Stage Lung Small Cell Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting the MAPK pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 68% (ClinicalTrials.gov NCT00554788).
Extensive Stage Lung Small Cell Cancer
Extensive Stage Lung Small Cell Cancer
Recruiting
targeting the MAPK pathway
DNA damage and the proportion of patients with severe DNA damage at 2 and 3 years from the end of therapy
biomarker for pre-conception counseling following cancer treatment
resistance to CPS, prompting a rational BEP rechallenge that resulted in disease stabilization and ultimately a durable long-term rem
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
BeiGene
Etoposide + Cisplatin/Carboplatin(BeiGene)은 Extensive Stage Lung Small Cell Cancer 표적 치료제로, Extensive Stage Lung Small Cell Cancer 영역에서 개발·상용화 중입니다. 작용기전: targeting the MAPK pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 68% (ClinicalTrials.gov NCT00554788).
Extensive Stage Lung Small Cell Cancer
Extensive Stage Lung Small Cell Cancer
Recruiting
targeting the MAPK pathway
DNA damage and the proportion of patients with severe DNA damage at 2 and 3 years from the end of therapy
biomarker for pre-conception counseling following cancer treatment
resistance to CPS, prompting a rational BEP rechallenge that resulted in disease stabilization and ultimately a durable long-term rem
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.